KADOR - A French retrospective study describing the epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer.

Head: Roche Medical Data Center

Collaborations

Last update: 08/23/2022 | Version: 1 | ID: 74138

Identification	Last update : 08/23/2022 Version : 1 ID :	74138
Detailed name A French retrospective study describing the epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer. Sign or acronym KADOR CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation General Aspects Medical area Cancer research Study in connection with Covid-19 Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Address 4 cours de I'lle Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	General	
epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer. Sign or acronym KADOR CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation General Aspects Medical area Cancer research Study in connection with Covid-19 Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	Identification	
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation General Aspects Medical area Cancer research Study in connection with Covid-19 Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	Detailed name	epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant
number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation General Aspects Medical area Cancer research Study in connection with Covid- 19 Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Roche Medical Data Center Address 4 cours de l'Ile Seguin - 92650 BOULOGNE- BILLANCOURT Email data_sharing_france@roche.com	Sign or acronym	KADOR
Medical area Cancer research Study in connection with Covid- 19 Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Roche Medical Data Center Address 4 cours de l'Ile Seguin - 92650 BOULOGNE- BILLANCOURT Email data_sharing_france@roche.com	number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency)	ML41346
Study in connection with Covid- 19 Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Address 4 cours de l'Ile Seguin - 92650 BOULOGNE- BILLANCOURT Email data_sharing_france@roche.com	General Aspects	
Pathology (details) Early HER2+ Breast cancer Health determinants Medicine Keywords KADOR Scientific investigator(s) (Contact) Name of the director Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	Medical area	Cancer research
Health determinants Keywords KADOR Scientific investigator(s) (Contact) Name of the director Address Addr		No
Keywords KADOR Scientific investigator(s) (Contact) Name of the director Roche Medical Data Center Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	Pathology (details)	Early HER2+ Breast cancer
Scientific investigator(s) (Contact) Name of the director Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	Health determinants	Medicine
Name of the director Roche Medical Data Center Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com	Keywords	KADOR
Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT Email data_sharing_france@roche.com		
BILLANCOURT Email data_sharing_france@roche.com	Name of the director	Roche Medical Data Center
	Address	
Organization Roche SAS	Email	data_sharing_france@roche.com
	Organization	Roche SAS

Participati	on ir	projects,
networks	and	consortia

No

_	110	
Fun	di	na
	9	9

Funding status Private

Governance of the database

Sponsor(s) or organisation(s) responsible

Roche SAS

Organisation status

Private

Presence of scientific or steering committees

Yes

Additional contact

Name of the contact

https://www.roche.fr/fr/innovation-recherchemedicale/data-sharing-portail-d-informationpartage-des-donnees.html

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried

out by an intermediary

A selection of health institutions and services

Database recruitment is is made

on the basis of:

Medication(s) taken

Database recruitment is carried out as part of an interventional

study

No

Database objective

Main objective

Primary objective: To describe therapeutic management of HER2-positive early breast cancer adults' patients who have received an adjuvant treatment following Herceptin® based neoadjuvant therapy and breast surgery.

Secondary objectives:

The 2 key secondary objectives are:

1. To describe the clinical characteristics of the

patients included in the cohort, overall and per pathological response status;

2. To measure the invasive disease-free survival (IDFS) and overall survival (OS), according to pathologic response status.

Other objectives:

- 3. To characterize adjuvant treatment failure outcomes including death, disease progression, and relapses;
- 4. To describe health care resources utilization by the targeted patients;
- 5. To estimate the number of HER2-positive early breast cancer patients who underwent breast surgery following Herceptin® based neoadjuvant treatment in France over a year (through the constitution of a registry of these patients) and number of HER2 positive early breast cancer patients with non pCR.

Inclusion criteria

Inclusion criteria:

- A confirmed diagnosis of HER2-positive early breast cancer;
- Initiated Herceptin® based neoadjuvant treatment during 2014 (inclusion period) followed by a breast surgery;
- A visit to any of the oncologist participating in the study during the 1-year inclusion period.

Exclusion criteria:

-Patients with bilateral breast cancer, or participating in a clinical trial for neoadjuvant or adjuvant treatment, or already included in the registry of another participating site of the study, or who expressed disagreement on the use of their medical data will be excluded from the site's registry.

Population type

Age

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered

Sick population

Pathology

D05 - Carcinoma in situ of breast

Gender

Woman

Geography area

National

Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2014
Date of last collection (YYYY or MM/YYYY)	2018
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	301
Data	
Database activity	Data collection completed
Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Neoadjuvant treatment strategy and non-drugs treatments (surgery and radiotherapy) - Adjuvant treatment strategy and modification - Inclusion criteria variables, demographic, anthropometric, clinical and cancer characteristics - Weight, comorbidities of interest at the time of adjuvant treatment initiation - Date of last visit of the patient during the follow-up period, disease progression and reason for earlier end of observation or follow-up - Health care resources utilizations - Start and end date of patient inclusion in the registry - Date of inclusion of the first patient included and the last patient included in the registry - Number of consultations at the site during the inclusion year - Adjuvant treatment with trastuzumab (yes/No) - Type of surgery and pathologic response status.
Presence of a biobank	No
Health parameters studied	Health care consumption and services
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	eCRF

Classifications used	CDISC
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	https://www.roche.fr/fr/innovation-recherche- medicale/data-sharing-portail-d-information- partage-des-donnees.html
Presence of document that lists variables and coding procedures	Yes
	Access on specific project only
Access to aggregated data	Access on specific project only